MedTrace Logo

A Phase I/II Study to Evaluate XNW34017 in Patients With Advanced or Metastatic Solid Tumor

NCT07327294 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2026-01-08

No results posted yet for this study

Summary

This study is an open-label, dose-escalation, multicenter Phase I/II study conducted in patients with advanced solid tumors. The target population for this study consists of patients with advanced solid tumors who have failed or are intolerant to standard treatments. The study is divided into two parts: the dose-escalation phase and the dose-expansion phase.

Conditions

Interventions

DRUG

XNW34017

Drug Name: XNW34017 Tablets Dosage Form: Tablet Strength: 5 mg, 50 mg Route of Administration: Oral Storage Instructions: Store in a sealed container, protected from light, at temperatures not exceeding 30°C.

Sponsors & Collaborators

  • Evopoint Biosciences Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-31
Primary Completion
2027-12-31
Completion
2028-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07327294 on ClinicalTrials.gov